Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 6/20 | 0.54 |
| ▸ | CDK2 | P24941 | 6/20 | 0.54 |
| ▸ | MARK3 | P27448 | 3/20 | 0.39 |
| ▸ | MARK4 | Q96L34 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | CTSE | P14091 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21840670 | 1.00 | CCNE1 (0.54) | CCNE1CDK2MARK3MARK4MEN1 | |
| SCHEMBL21840684 | 0.82 | CCNE1 (0.52) | CCNE1CDK2MARK3MARK4ALDH1A1 | |
| SCHEMBL21840668 | 0.79 | CYP1A2 (0.40) | CCNE1CDK2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL21840641 | 0.72 | CCNE1 (0.80) | CCNE1CDK2 | |
| SCHEMBL29390334 | 0.72 | CCNE1 (0.80) | CCNE1CDK2 | |
| SCHEMBL21840671 | 0.71 | CDK2 (1.00) | CCNE1CDK2MARK3MARK4 | |
| SCHEMBL29390896 | 0.71 | CDK2 (1.00) | CCNE1CDK2MARK3MARK4 | |
| SCHEMBL29390921 | 0.69 | CDK2 (0.71) | CCNE1CDK2MARK3MARK4 | |
| SCHEMBL25045063 | 0.64 | KDM4E (0.41) | CCNE1CDK2MARK3MARK4MEN1 | |
| SCHEMBL22165209 | 0.64 | CCNE1 (0.41) | CCNE1CDK2MARK3MARK4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866432-B2 | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2024-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866432-B2 | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors | CDK2, CDK4, CDK3 | CCNE1 35/4885CDK2 1/4885MARK3 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.